**Core Concept**
The underlying principle being tested is the pathophysiology of myasthenia gravis, an autoimmune disease characterized by **anti-acetylcholine receptor (AChR) antibodies** that disrupt neuromuscular transmission. This disruption is due to the reduction in the number of available **AChRs** at the **neuromuscular junctions**. The disease involves **immune-mediated destruction** of AChRs.

**Why the Correct Answer is Right**
Although the specific correct answer choice is missing, the mechanism typically involves **complement-mediated lysis** and **antibody-dependent cellular cytotoxicity**, leading to the destruction of the **postsynaptic membrane** and a reduction in AChR density. This results in decreased **neuromuscular transmission** efficiency, as there are fewer receptors available for **acetylcholine (ACh)** to bind to, thereby inducing muscle weakness.

**Why Each Wrong Option is Incorrect**
**Option A:** Would be incorrect if it suggested a mechanism not involving immune-mediated destruction or complement activation.
**Option B:** Might be wrong if it proposed a direct inhibition of AChR function rather than reduction in receptor number.
**Option C:** Could be incorrect if it implied an increase in AChR turnover without immune system involvement.
**Option D:** Might be incorrect if it suggested a mechanism unrelated to antibody-mediated destruction of AChRs.

**Clinical Pearl / High-Yield Fact**
Myasthenia gravis is a classic example of an autoimmune disease where **anti-AChR antibodies** lead to **fluctuating muscle weakness**, worsening with activity and improving with rest. A key clinical feature is **ptosis** (drooping of the eyelids), which is often one of the earliest symptoms.

**Correct Answer:** D. Complement-mediated lysis and modulating AChR turnover through cross-linking.